New immune cell attack tested for tough blood cancers
NCT ID NCT07225439
Summary
This early-stage study is testing the safety of a new combination treatment for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment adds an experimental therapy—'natural killer' (NK) immune cells from a donor—to standard lymphoma drugs. The main goal is to find a safe dose of these donor cells, while also checking if the treatment helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
Contact
-
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.